CATRENE Programme to Succeed MEDEA+ as European Nanoelectronics R&D Champion

MEDEA+, the EUREKA pan-European Programme for advanced co-operative Research and Development in Microelectronics, today announced details of the new EUREKA programme called CATRENE (Cluster for Application and Technology Research in Europe on NanoElectronics) that will take up the challenge of increasing Europe's strength in micro- and nanoelectronics after the highly successful MEDEA+ programme reaches its conclusion in 2008. A public/private partnership aimed at ensuring the continued development of European expertise in semiconductor technology and applications, CATRENE will build on the success of MEDEA+ and the previous EUREKA programmes JESSI and MEDEA in fostering the continued development of a dynamic European ecosystem with the critical mass necessary to compete at a global level in high technology industries as these move into the era of nanoelectronics.

Since its inception in 2001, MEDEA+ has made significant contributions to establishing and maintaining European leadership in fields ranging from smart card and image sensing technologies to automotive electronics. European IC companies have successfully developed three basic CMOS process generations in a time schedule in line with or even ahead of the global ITRS roadmap. Three European semiconductor companies are ranked amongst the world wide top ten and Europe's semiconductor industry has 10% of the world wide market. European champions with a strong global market position as wafer processing equipment suppliers, lithography tool and infrastructure suppliers as well as substrate and material suppliers have been added to the industrial landscape.

Like MEDEA+, CATRENE embraces all key actors in the value chain - including applications, technology, materials and equipment suppliers - as well as involving industrial companies of all sizes, universities and other research institutions, supported by Public Authorities. In this way CATRENE will benefit from the strong infrastructure for cross-border cooperation that has been developed by MEDEA+ and its predecessors.

An important feature of CATRENE is the concept of Lighthouse Projects, which address major socioeconomic needs such as transportation, healthcare, security, energy and entertainment through focussed R&D programmes. In the foreseeable future, the role of electronics and information systems will further increase as European society is faced with structural problems such as ageing of the population, exploding healthcare cost, transportation bottlenecks, rising energy costs and the need to increase productivity to be competitive on a worldwide basis. These societal challenges are also major opportunities for European industry and are designed to help European companies to address these new lead markets and to become worldwide market leaders. The "umbrella" lighthouse projects will serve as a focus for specific technology and applications development projects that address these challenges.

"For more than a decade, the EUREKA JESSI, MEDEA and MEDEA+ programmes have made it possi-ble for Europe's industry to reinforce its position in semiconductor process technology, manufac-turing and applications, and to become a key supplier to markets such as telecommunications, consumer electronics and automotive electronics", said Jozef Cornu, Chairman of MEDEA+ and designated Chairman of CATRENE. "Nanoelectronics will offer enormous opportunities to those who are the first to master and bring to market new technologies and applications and we believe that CATRENE will play a vital role in helping Europe's microelectronics industry to go from strength to strength."

While the JESSI, MEDEA and MEDEA+ programmes were divided into technology and applications sub-programmes, CATRENE recognises the increasing convergence of technology and applications. It will therefore focus on large identified application markets, deriving from these the roadmap of required technologies. Key technology goals include maintaining and increasing Europe's strength in IP (Intellectual Property) across the entire electronics supply chain and its leadership in lithography and Silicon-on-Insulator materials; ensuring that European companies are among the world leaders in the advanced semiconductor technologies that allow entire systems to be integrated in a single package; and strengthening European expertise in applying a deep knowledge of semiconductor process technology to efficient design for new electronics applications.

For more information on MEDEA+ and CATRENE visit http://www.medeaplus.org.

About MEDEA+
The MEDEA+ programme (2001-2008) comprised 77 projects involving 20,000 person-years and around 450 partner organisations from large companies (38 %), SMEs (37%), institutes and academia (25%). It delivered important innovations in key application areas such as automotive and traffic control, broadband communications, secure society, energy saving and healthcare.

About CATRENE
CATRENE is a four-year programme, starting 1 January 2008 and extendable by another four years. This is in line with the changing landscape of the semiconductor industry as well as the present view on technology evolution and the time span over which most of the major applications will develop. Resources required will be annually around 4,000 person-years, equalling about € 6 billion for the extended programme.

Most Popular Now

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

AI Unlocks Genetic Clues to Personalize …

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes - insights that could help doctors tailor...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

Deep Learning to Increase Accessibility…

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...

To be Happier, Take a Vacation... from Y…

Today, nearly every American - 91% - owns a cellphone that can access the internet, according to the Pew Research Center. In 2011, only about one-third did. Another study finds...

Researchers Find Telemedicine may Help R…

Low-value care - medical tests and procedures that provide little to no benefit to patients - contributes to excess medical spending and both direct and cascading harms to patients. A...